Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Mesoblast Stock Is Tanking Today

By Keith Speights - Dec 15, 2020 at 12:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company reported disappointing results from a late-stage clinical study.

What happened

Shares of Mesoblast Limited ( MESO 0.68% ) were tumbling 19.6% lower as of 12:41 p.m. EST on Tuesday. The big drop came after the company announced Monday evening that its off-the-shelf cell therapy candidate rexlemestrocel-L (Revascor) failed to meet the primary endpoint of a late-stage clinical study targeting the treatment of advanced chronic heart failure.

So what

Mesoblast said that Revascor didn't achieve any reduction in recurrent non-fatal decompensated heart-failure events. Decompensated heart failure occurs when structural changes in the heart cause obvious symptoms. The problem was that this reduction was the primary endpoint of the company's late-stage study.

Electrocardiagram line

Image source: Getty Images.

However, Mesoblast did find some positives in its clinical trial. The Australia-based biotech stated that patients in the study achieved a 60% reduction in the incidence of heart attacks or strokes, as well as a 60% reduction in death from cardiac causes when treated early with Revascor in combination with other therapies.

Mesoblast CEO Silviu Itescu highlighted these positives, stating, "The reduction in mortality seen with rexlemestrocel-L in advanced chronic heart failure underlines the power of this technology and the commitment of Mesoblast to address diseases in patients with high unmet need which are refractory to existing therapies."

Now what

It's possible that the biotech stock could rebound from today's sell-off. Mesoblast now plans to meet with the U.S. Food and Drug Administration (FDA) about a possible path to approval for Revascor in treating advanced chronic heart failure based on mortality reduction.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mesoblast Limited Stock Quote
Mesoblast Limited
$5.91 (0.68%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.